Dual Role of CCR2 During Initiation and Progression of Collagen-induced Arthritis: Evidence for Regulatory Activity of CCR2+ T Cells
Overview
Authors
Affiliations
Chemokines play an important role in the recruitment of leukocytes and have recently been shown to also attract regulatory T cells. Using blocking mAbs, we analyzed the role of the chemokine receptor CCR2 during initiation and progression of collagen-induced arthritis in mice. Blockade of CCR2 from days 0 to 15 markedly improved clinical signs of arthritis and histological scores measuring leukocyte infiltration, synovial hyperplasia, and bone and cartilage erosion. CCR2 blockade during disease initiation significantly reduced plasma titers of collagen Abs in vivo. In vitro CCR2 blockade also interfered with collagen-specific activation and proliferation of T cells. Surprisingly, CCR2 blockade from days 21 to 36 markedly aggravated clinical and histological signs of arthritis and increased the humoral immune response against collagen. We show that CCR2 is expressed on regulatory T cells. Purified CCR2+ T cells are fully anergic toward polyclonal and collagen-specific activation and potently suppress activation of other T and B cells. The subpopulation of CCR2+ CD25+ regulatory T cells increases approximately 5-fold in the progression phase, while CCR2 expression on other leukocyte populations remains unchanged. These findings identify CCR2+ T cells as regulatory T cells and indicate that CCR2 also plays an important role in down-modulating an inflammatory response.
Durable lymph-node expansion is associated with the efficacy of therapeutic vaccination.
Najibi A, Lane R, Sobral M, Bovone G, Kang S, Freedman B Nat Biomed Eng. 2024; 8(10):1226-1242.
PMID: 38710838 PMC: 11485260. DOI: 10.1038/s41551-024-01209-3.
Akbarzadeh R, Czyz C, Thomsen S, Schilf P, Murthy S, Sadik C Front Immunol. 2023; 14:1241461.
PMID: 38116004 PMC: 10728641. DOI: 10.3389/fimmu.2023.1241461.
Cardiac resident macrophages: key regulatory mediators in the aftermath of myocardial infarction.
Chen C, Wang J, Liu C, Hu J Front Immunol. 2023; 14:1207100.
PMID: 37457720 PMC: 10348646. DOI: 10.3389/fimmu.2023.1207100.
Na H, Lee S, Lee D, Woo J, Choi S, Cho K J Transl Med. 2022; 20(1):428.
PMID: 36138477 PMC: 9503236. DOI: 10.1186/s12967-022-03515-3.
Ozkan H, di Francesco M, Willcockson H, Valdes-Fernandez J, Di Francesco V, Granero-Molto F Drug Deliv Transl Res. 2022; 13(2):689-701.
PMID: 36109442 PMC: 9794532. DOI: 10.1007/s13346-022-01235-1.